Table 1 Cell line characterization
From: Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
| Â | BRAF | Other oncogenic events |
|---|---|---|
M229 | BRAF V600E homozygous | BRAF amp., AKT amp., PTEN heterozygous, MITF amp. |
M229AR9 | BRAF V600E homozygous | BRAF amp., AKT amp., PTEN heterozygous, MITF amp. |
M233 | BRAF V600E heterozygous | BRAF amp., AKT1 amp., CCND1 amp., EGFR amp., CDKN2A homo, PTEN null |
M238 | BRAF V600E heterozygous | CDKN2A homozygous, PTEN heterozygous |
M238AR | BRAF V600E heterozygous | CDKN2A homozygous, PTEN heterozygous |
M249 | BRAF V600E heterozygous | BRAF amp., MITF amp., AKT2 amp., PTEN null |
M255 | BRAF V600E heterozygous | AKT2 amp., CCND1 amp., EGFR amp., CDKN2A homozygous |
M262 | BRAF V600E homozygous | AKT1 E17K, AKT amp., EGFR amp., CDKN2A homozygous |
M263 | BRAF V600E heterozygous | CDKN2A heterozygous |
M299 | BRAF V600E heterozygous | Â |
M308 | BRAF V600E heterozygous | BRAF amp., MITF amp., AKT2 amp., EGFR amp., CDKN2A heterozygous |
M370 | BRAF V600E heterozygous | Â |
M397 | BRAF V600E heterozygous | PTEN null |
M397AR | BRAF V600E heterozygous | PTEN null |
M399 | BRAF V600E heterozygous | PTEN null |
M406 | BRAF V600E heterozygous | N/T |
M407 | BRAF V600E heterozygous | N/T |
M409 | BRAF V600E heterozygous | N/T |
M409AR | BRAF V600E heterozygous | N/T |
M410 | BRAF V600E heterozygous | N/T |
M411 | BRAF V600E homozygous | PTEN null |
M414 | BRAF V600K | Â |
M424 | BRAF V600K | Â |
N/T: Not tested | Â | Â |